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ABSTRACT  
A simple, novel, precise and accurate stability indicating RP-HPLC method was 
developed and validated for the estimation of Ulipristal Acetate in pharmaceutical 
dosage form. A Phenoxneome C18 (150 mm x 4.6 mm, 5 µm) column was used as 
stationary phase with mobile phase consisting of 0.1% ortho phosphoric acid and 
acetonitrile in the ratio of 50:50 v/v (pH was adjusted to 4.0 with triethyl amine). 
The flow rate was maintained at 1.0 mL/min and effluents were monitored at 223 
nm. The retention time was 1.895 min. The linearity of the method was observed in 
the concentration range of 20-100 µg/mL with correlation coefficient of 0.999. The 
method developed was validated for linearity, precision, accuracy, system 
suitability and forced degradation studies like acidic, alkaline, oxidative and 
neutral stress conditions were performed as per ICH guidelines. The results 
obtained in the study were within the acceptable limits and hence this method can 
be used for the estimation of Ulipristal Acetate in pharmaceutical dosage form. 
INTRODUCTION
Ulipristal Acetate (Figure 1) is the selective 
progesterone receptor modulator (SPRM) for the 
treatment of uterine fibroids and also used as 
medication for emergency birth control [1]. 
Chemically it is [(8S,11R,13S,14S,17R)-17-acetyl-
11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-
1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta 
[a]phenanthren-17-yl] acetate. Ulipristal Acetate 
prevents progesterone from binding to the 
receptor, leading to blockage of gene transcription 
inhibiting synthesis of proteins necessary to begin 
and maintain pregnancy and also acts by inhibiting 
the ovulation. [2-4] 
Literature survey revealed that few HPLC methods 
[5-6] were reported for the estimation of Ulipristal 
Acetate in pharmaceutical formulations. Hence a 
new, sensitive and efficient HPLC method was 
developed and validated as per ICH guidelines [7-8] 
for the estimation of Ulipristal Acetate in bulk and 
pharmaceutical dosage form. 
 
 
MATERIALS AND METHODS 
Instrumentation  
To develop a high pressure liquid chromatographic 
method for quantitative estimation of Ulipristal 
Acetate using Agilent Technologies 1260 infinity 
binary HPLC instrument on a Phenoxneome C18 
(150 mm x 4.6 mm, 5 µm) analytical column was 
used. The instrument is equipped with a pump, 
sampler and PDA detector. A 20 μL rheodyne 
injector port was used for injecting the samples. 
Data was analyzed by using EZ Chrome Open Lab 
software. 
Chemicals and solvents  
The reference sample of Ulipristal Acetate was 
obtained from Shree Icon Pharmaceutical 
Laboratories, Vijayawada, India. Commercially 
available Ulipristal Acetate tablets claimed to 
contain 5 mg of Ulipristal Acetate was purchased 
from local market. Methanol (HPLC grade), 
acetonitrile (HPLC grade), ortho phosphoric acid 
(AR grade) and triethyl amine (AR grade) were 
purchased from Merck (India) Ltd, Mumbai, India. 
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Chromatographic conditions  
A mixture of 0.1% ortho phosphoric acid: 
acetonitrile (50:50 v/v, pH 4.0 was adjusted with 
triethyl amine) was found to be the most suitable 
mobile phase for ideal chromatographic separation 
of Ulipristal Acetate. The solvent mixture was 
filtered and sonicated before use for 5 minutes. It 
was pumped through the column at a flow rate of 
1.0 mL/min. Injection volume was 20 µL and the 
column was maintained at ambient temperature. 
The column was equilibrated by pumping the 
mobile phase through the column for at least 30 
minutes prior to the injection of the drug solution. 
The detection of the drug was monitored at 223 nm. 
The run time was set at 5 min.  
Preparation of mobile phase and diluent  
500 mL of the 0.1% ortho phosphoric acid (pH 
adjusted to 4.0 with triethyl amine) buffer was 
mixed with 500 mL of acetonitrile. The solution was 
degassed in an ultrasonic water bath for 5 minutes 
and filtered through 0.45 µm filter under vacuum. 
The water and acetonirile phase was used as 
diluent. 
Preparation of standard solution  
About 10 mg of Ulipristal Acetate is accurately 
weighed and transferred into a 10 mL (1000 
µg/mL) clean dry volumetric flask containing 
mobile phase. The solution was sonicated for 5 min 
and the drug was dissolved completely. The volume 
was made up to the mark with a further quantity of 
the mobile phase to get a stock concentration of 
Ulipristal Acetate. Further pipette 1.0 mL of the 
above stock solution into a 10 mL volumetric flask 
(100 µg/mL) and the volume was made up to the 
mark with the mobile phase. 
Preparation of sample solution  
20 tablets were weighed and finely powdered. An 
accurately weighed portion of powder sample 
equivalent to 10 mg of Ulipristal Acetate is 
transferred into a 10 mL (1000 µg/mL) clean dry 
volumetric flask containing mobile phase. The 
solution was filtered and sonicated for 5 min. The 
volume was made up to the mark with a further 
quantity of the mobile phase to get a stock 
concentration of Ulipristal Acetate. Further pipette 
0.6 mL of the above stock solution into a 10 mL 
volumetric flask (60 µg/mL) and the volume was 
made up to the mark with the mobile phase.  
METHOD VALIDATION 
Linearity  
Linearity was performed by preparing standard 
solution of Ulipristal Acetate at different 
concentration levels i.e., 20-100 µg/mL. The 
absorbance was measured at 223 nm. Each 
measurement was carried out in triplicate. Linearity 
was proven by regression analysis by the least 
square method.   
Precision  
Precision is the degree of repeatability of an 
analytical method under normal operational 
conditions. The intermediate precision of the 
method was confirmed by intra-day and inter-day 
analysis. The concentration used for the precision 
studies is 60 µg/mL. To study the intra-day and 
inter-day precision, the analysis of drugs was 
repeated for six times in the same day and in 
different days. Six replicate mixed standard solution 
of Ulipristal Acetate was measured with the same 
concentration and the %RSD was calculated.  
Accuracy  
The accuracy of the method was assessed by 
recovery study of Ulipristal Acetate in the dosage 
form at three concentration levels. A known amount 
of standard drug was added to the fixed amount of 
pre-analyzed drug sample solution. Percent 
recovery was calculated by comparing the peak 
area before and after the addition of the standard 
drug. The standard addition method was performed 
at three concentration levels in triplicate at 80%, 
100% and 120%.  
System suitability  
Standard solutions were prepared as per the test 
method and injected into the chromatographic 
system. The system suitability parameters like 
theoretical plates, resolution and asymmetric factor 
were evaluated.  
Limit of detection and limit of quantitation  
The limit of detection (LOD) and limit of 
quantitation (LOQ) of the developed method were 
determined by injecting progressively low 
concentrations of the standard solution using the 
developed HPLC method.  
Ruggedness  
The ruggedness of the method was determined by 
carrying out the experiment on different 
instruments by different operators using different 
columns of similar types. Samples of Ulipristal 
Acetate at 60 µg/mL concentration were analyzed 
by different analysts.  
Robustness 
To demonstrate the robustness of the method, the 
solution was prepared as per test method and 
injected at different variable conditions like 
changes in flow rate, wavelength, mobile phase 
composition and pH.  
STABILITY STUDIES 
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Degradation studies were performed and the 
degraded samples were injected. 
Control sample  
20 tablets were weighed and finely powdered. An 
accurately weighed portion of powder sample 
equivalent to 10 mg of Ulipristal Acetate is 
transferred into a 10 mL (1000 µg/mL) clean dry 
volumetric flask containing mobile phase. The 
solution was filtered and sonicated for 5 min. The 
volume was made up to the mark with a further 
quantity of the mobile phase to get a stock 
concentration of Ulipristal Acetate. Further pipette 
0.6 mL of the above stock solution into a 10 mL 
volumetric flask and the volume was made up to the 
mark with the mobile phase.  
Acid d egradation s tudies  
To 1 mL of stock solution of Ulipristal Acetate, 1 mL 
of 2N hydrochloric acid was added and refluxed for 
30 mins at 600C. The resultant solution was diluted 
to obtain 60 µg/mL solution and 20 µL solution 
were injected into the system and the 
chromatograms were recorded to assess the 
stability of sample. 
 
Alkali d egradation s tudies  
To 1 mL of stock solution of Ulipristal Acetate, 1 
mL of 2N sodium hydroxide was added and 
refluxed for 30 mins at 600C. The resultant 
solution was diluted to obtain 60 µg/mL solution 
and 20 µL solution were injected into the system 
and the chromatograms were recorded to assess 
the stability of sample. 
Oxidative degradation studies  
To 1 mL of stock solution of Ulipristal Acetate, 1 
mL of 20% hydrogen peroxide was added. The 
solution were kept for 30 mins at 600C. The 
resultant solution was diluted to obtain 60 
µg/mL solution and 20 µL solution were injected 
into the system and the chromatograms were 
recorded to assess the stability of sample. 
Neutral d egradation s tudies  
Stress testing under neutral conditions was studied 
by refluxing the s t a n d a r d  U l i p r i s t a l  
A c e t a t e  s o l u t i o n  in water for 6 h r s  at a 
temperature of 60ºC. The resultant solution was 
diluted to obtain 60 µg/mL solution and 20 µL 
solution were injected into the system and the 
chromatograms were recorded to assess the 
stability of sample. 
 
Fig. 1: Chemical structure of Ulipristal Acetate  
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Fig. 2: Linearity curve of Ulipristal Acetate 
 
Fig. 3: Typical chromatogram of Ulipristal Acetate  
 
Fig. 4: Chromatogram of Ulipristal Acetate in acid degradation  
 
Fig. 5: Chromatogram of Ulipristal Acetate in alkali degradation 
 
Fig. 6: Chromatogram of Ulipristal Acetate in oxidative degradation 
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Fig. 7: Chromatogram of Ulipristal Acetate in neutral degradation 
Table 1: Optimized chromatographic conditions of Ulipristal Acetate 
Parameter Condition 
Mobile phase Ortho phosporic acid:Acetonitrile (50:50 v/v) 
pH 4.0 
Diluent Water:Acetonitrilee  
Column Phenoxneome C18 (150 mm × 4.6 mm, 5 µm) 
Column temperature Ambient 
Wave length 223 nm 
Injection volume 20 µL 
Flow rate 1.0 mL/min 
Run time 5 min 
Retention time 1.895 min 
                      Table 2: Linearity results of Ulipristal Acetate  
S. No. Concentration (µg/mL) Peak area  
1 0 0 
2 20 84667 
3 40 16510 
4 60 24954 
5 80 33986 
6 100 42760 
Slope 42687 
Intercept 23018 
Regression Equation (y) y=42687x-23018 
Correlation Coefficient 0.999 
Table 3: Precision results for Ulipristal Acetate  
S. No. 
Intra-day 
Peak area 
Inter-day 
Peak area 
Time (Hours) Time (Days) 
1 0 2425428 
Day1 (n=3) 2221391 
2 3 2468027 
3 6 2430414 
Day 2 (n=3) 2185709 
4 9 2424927 
5 12 2396338 
Day 3 (n=3) 2219279 
6 15 2397420 
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Mean 2423759 Mean 2208793 
SD 26282.12 SD 20019 
%RSD 1.084 %RSD 0.906 
Table 4: Recovery results of Ulipristal Acetate  
Recovery/Spike 
level at about [%] 
Amount of Drug 
added (µg/mL) 
Amount of Drug 
found (µg/mL) 
% 
Recovery 
80 40 39.26 98.15 
100 60 60.87 101.45 
120 100 99.87 99.87 
Table 5: System suitability parameters of Ulipristal Acetate 
Parameter Results 
Linearity range (μg/mL) 20-100 
Correlation coefficient 0.999 
Theoretical plates (N) 2300 
Tailing factor 1.5 
LOD (μg/mL) 0.064 
LOQ (μg/mL) 0.190 
   Table 6: Forced degradation study results of Ulipristal Acetate 
Stress conditions  %Assay %Degradation 
Control 100 - 
Acid 87.60 12.40 
Alkali  76.10 23.90 
Oxidative  46.37 53.63 
Neutral 94.94 05.06 
   
RESULTS AND DISCUSSION 
In the present work, a simple, novel, precise and 
accurate stability indicating RP-HPLC method has 
been optimized, developed and validated for the 
determination of Ulipristal Acetate in 
pharmaceutical formulations by using 
Phenoxneome C18 (150 mm x 4.6 mm, 5µm) in 
isocratic mode with mobile phase composed of 
mixture of 0.1% ortho phosphoric acid and 
acetonitrile in the ratio of 50:50 v/v (pH 4.0 was 
adjusted with triethyl amine)  resulted the 
chromatographic peak obtained was in good shape, 
better resolved and almost free from tailing. The 
flow rate was 1.0 mL/min and the drug component 
was measured with PDA detector at 223 nm. The 
results of optimized HPLC conditions were shown 
in Table 1.  
The method was linear in the range of 20 to 100 
µg/mL for Ulipristal Acetate with correlation 
coefficient of 0.999. The linearity results were 
shown in Table 2 and the linearity curve was shown 
in Figure 2. The %RSD for the intra-day and inter-
day precision for Ulipristal Acetate was found to be 
1.084 and 0.906, which indicates the method is 
precise. The results of precision studies were 
shown in Table 3. The %recoveries of Ulipristal 
Acetate were found in the range of 98.15-101.45% 
and the %mean recovery was found to be 99.82%, 
which indicates the method is accurate. The results 
of recovery studies were shown in Table 4.  
The retention time of Ulipristal Acetate was 1.895 
min, cuts down on overall time of sample analysis 
and the method was more cost effective as it utilizes 
very less quantity of mobile phase.  The number of 
theoretical plates was 2300 and tailing factor was 
1.5 for Ulipristal Acetate, which indicates efficient 
performance of the column. Typical chromatogram 
of drug Ulipristal Acetate was shown in Figure 3. No 
interfering peaks were found in the chromatogram 
of the formulation within the run time indicating 
that excipients used in the formulation did not 
interfere with the estimation of the drug Ulipristal 
Acetate by the proposed HPLC method. 
Selectivity of the method was demonstrated by the 
absence of any interfering peaks at the retention 
time of the drug. The limit of detection and limit of 
quantitation for Ulipristal Acetate were found to be 
0.064 µg/mL and 0.190 µg/mL, which indicate the 
sensitivity of the method. A system suitability test 
was performed to evaluate the chromatographic 
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parameters and the summary of system suitability 
parameters were shown in Table 5. Validated 
method was applied for the determination of 
Ulipristal Acetate in commercial formulations.  
Stability studies of Ulipristal Acetate under different 
stress conditions indicated the following 
degradation behavior. In acidic degradation, the 
degradation product was appeared at retention 
time of 1.858 min and the %degradation is 12.40%. 
In alkali degradation, the degradation product was 
appeared at retention time of 1.847 min and the 
%degradation is 23.90%. In oxidative degradation, 
the degradation product was appeared at retention 
time of 1.833 min and the %degradation is 53.63%. 
In neutral degradation, the degradation product 
was appeared at retention time of 1.809 min and 
the %degradation is 5.06%. The results of stability 
studies were shown in Table 6. The typical 
chromatograms of degradation behavior of 
Ulipristal Acetate in different stress conditions are 
shown in Figure 4 to Figure 7.  
CONCLUSION 
The present study represents the development of a 
stability indicating RP-HPLC method for 
determination of Ulipristal Acetate by following the 
recommendations of ICH guidelines. The proposed 
method showed acceptable accuracy, precision, 
selectivity and wide linear concentration range. The 
results of analysis proved that the method is 
suitable for the determination of Ulipristal Acetate 
in bulk and tablet dosage form without any 
interference from the degradation products and it is 
recommended for routine quality control analysis of 
the Ulipristal Acetate in pharmaceutical 
formulation.    
REFERENCES 
1. Nicoletta B, Silvestro C, Antonio M, Marta 
D, Giuseppe LM, Roberto M. Evaluation of the 
pharmacological profile of Ulipristal Acetate, a 
novel pharmacological approach for treatment 
of uterine fibroids. Drug Design and 
Development Therapy.  2014; 8: 285-292. 
2. Pohl O, Zobrist RH, Gotteland JP. The clinical 
pharmacology and pharmacokinetics of 
Ulipristal Acetate for the treatment of uterine 
fibroids. Reproductive Sciences. 2015; 22: 476-
483. 
3. Pohl O, Osterloh I, Gotteland JP. Ulipristal 
Acetate- safety and pharmacokinetics following 
multiple doses of 10-50 mg per day. Journal of 
Clinical Pharmacy and Therapeutics. 2013; 
38(4): 314-320.  
4. Brache V, Cochon L, Jesam C, Maldonado R, 
Salvatierra AM, Levy DP, Gainer E, Croxatto HB. 
Immediate pre-ovulatory administration of 30 
mg Ulipristal Acetate significantly delays 
follicular rupture. Human Reproduction. 2010; 
25: 2256-2263. 
5. Gong A, Zhu X. Dispersive solvent-free 
ultrasound-assisted ionic liquid dispersive 
liquid-liquid micro extraction coupled with 
HPLC for determination of Ulipristal Acetate. 
Talanta. 2015; 131: 603-608.    
6. Shi JX, Zhu FY, Zou QG, Sun LL, Wei P. 
Determination of Ulipristal Acetate and its 
related substances by HPLC. Chinese Journal of 
New Drugs. 2014; 7: 839-842.   
7. ICH Harmonised Tripartite Guideline, Q2(R1). 
Validation of Analytical Procedures: Text and 
Methodology. International Conference on 
Harmonization, Geneva. 2005; 1-13.   
8. ICH Harmonised Tripartite Guideline, Q1A(R2). 
Stability testing of new drug substances and 
products. International Conference on 
Harmonization, Geneva. 2003; 1-18.   
 
 
 
 
 
 
 
 
Cite this article as:  
A. Lakshmana Rao, Alimunnisa, D. Sai Tejaswini, G. L. Vagdevi Jaya 
Lakshmi, V. Bhavya Naga Vani. Development and Validation of Stability 
Indicating HPLC Method for the Determination of Ulipristal Acetate in 
Pharmaceutical Dosage Form. International Journal of Research in 
AYUSH and Pharmaceutical Sciences, 2019;3(2):321-327. 
Source of support: Nil, Conflict of interest: None Declared 
 
*Address for correspondence 
Dr. A. Lakshmana Rao 
Professor and Principal 
V. V. Institute of Pharmaceutical 
Sciences, Gudlavalleru, Andhra 
Pradesh, India.  
Email: dralrao@gmail.com  
